FATE(Fate Therapeutics, Inc.) · 财务报表

FATE(Fate Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$55.85M$96.30M$63.53M$13.63M$6.65M
毛利润—————
营业利润−$216.99M−$308.39M−$190.51M−$210.28M−$147.70M
净利润−$212.15M−$281.72M−$160.93M−$186.26M−$136.31M
经营现金流−$162.87M−$248.21M−$132.26M−$122.87M−$106.08M
自由现金流−$213.57M−$283.77M−$138.42M−$123.60M−$112.04M
摊薄每股收益$-2.24$-2.91$-1.64$-1.64$-1.15

Fate Therapeutics, Inc. FATE